Evgen Pharma
Wilmslow, Cheshire, United Kingdom
About Evgen Pharma
Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: lse:EVG
- Website: evgen.com
- Phone: +44 151 705 3532
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/evgen-pharma-2204859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.